Q&A With US FDA Commissioner Scott Gottlieb
Executive Summary
US FDA Commissioner Scott Gottlieb sat down with the Pink Sheet and Medtech Insight reporters for an exclusive chat about his ongoing regulatory work and plans for the future.
You may also be interested in...
Rx Patent Reform Gets Renewed Interest From GOP As Alternative To Price Negotiation
A Republican congressman and witness discuss shortened IP protections while criticizing Nancy Pelosi's drug price negotiation plan.
Catalyst Alleges US FDA 'Facilitating' Off-Label Use With Jacobus' Ruzurgi Approval
Lawsuit seeking invalidation of rare disease treatment's approval in Lambert-Eaton myasthenic syndrome encompasses policy trifecta of exclusivity, drug pricing, and expanded access issues.
Real-World Evidence Could Speed Development Of Drugs Offering Incremental Improvements
US FDA Commissioner Gottlieb says common diseases need new treatments and argues streamlining trials may pique industry interest.